Why India Must Include the Typhoid Conjugate Vaccine in Its Universal Immunisation Programme: A Public Health Imperative

India, grappling with a significant typhoid burden, is at a critical juncture to adopt the Typhoid Conjugate Vaccine (TCV) into its Universal Immunisation Programme (UIP) to safeguard millions, especially children, from this preventable disease. The National Technical Advisory Group on Immunisation (NTAGI) recommended TCV inclusion in 2022, yet broader implementation awaits, amid compelling evidence supporting its safety, cost-effectiveness, and public health benefits.

Typhoid Burden in India: The Urgent Public Health Challenge

Typhoid fever remains endemic in India, with prevalence particularly high among children under five and those living in urban slums with poor sanitation. Surveillance data estimate incidence rates up to 377 per 100,000 person-years in young children aged 2 to 4 years. The disease, caused by Salmonella Typhi, frequently leads to prolonged fever, intestinal complications, and if untreated, death. Antibiotic resistance in Salmonella Typhi strains further complicates treatment, underscoring the need for preventive strategies beyond therapeutics.​

Typhoid Conjugate Vaccine: Science and Effectiveness

The Typhoid Conjugate Vaccine, a newer generation vaccine, uses a Vi polysaccharide conjugated to a protein carrier, enhancing immune response in young children and providing longer-lasting protection compared to older vaccines. Real-world studies demonstrate its vaccine effectiveness at around 80-87% against culture-confirmed typhoid fever. The vaccine also exhibits an excellent safety profile, being compatible with other routine childhood immunizations.​

Evidence Supporting TCV Inclusion in the UIP

The NTAGI’s 2022 recommendation for TCV introduction in the UIP is supported by multiple peer-reviewed studies synthesizing vaccine benefits. Literature reviews highlight the following:

• Disease Burden Reduction: Introduction of TCV can prevent 17% to 36% of typhoid cases and deaths in urban settings, with gains in life years and quality-adjusted life years (QALYs).​

• Cost-effectiveness: Economic modeling shows TCV to be cost-saving in urban India, delivering healthcare savings by averting treatment costs and productivity losses. Although cost-effectiveness in rural areas is less pronounced, long-term vaccine efficacy improves its economic value.​

• Implementation Feasibility: The TCV can be integrated into existing immunisation schedules, with healthcare providers generally accepting its co-administration with other vaccines, albeit some evidence gaps remain.​

Expert Perspectives

Dr. Venkatesh Mogasale, an epidemiologist specializing in vaccine policy, states, “The inclusion of TCV in India’s UIP is an evidence-based strategy that addresses a major neglected disease burden, especially in children. Besides direct health benefits, it mitigates the threat of antimicrobial resistance by reducing typhoid incidence.” Independent experts in infectious diseases and public health emphasize the urgency of nationwide rollout to achieve equitable protection across all socio-economic strata.​

Public Health Implications

Expanding access to TCV through the UIP can substantially decrease disease transmission, reduce hospitalizations, and alleviate pressure on healthcare systems. This aligns with global public health goals to control enteric fevers in low- and middle-income countries. Vaccination also helps protect vulnerable populations, including young children and those residing in high-risk urban slums, thereby promoting health equity.​

Limitations and Considerations

While the case for TCV is strong, research indicates certain evidence gaps needing attention. Limited country-specific data on vaccine demand forecasting, budget impact analysis, and provider acceptability persist. Additionally, ongoing surveillance is required to monitor vaccine impact on antimicrobial resistance patterns and to assess safety when co-administered with other vaccines.​

What This Means for Indian Families

For parents and caregivers, TCV inclusion in UIP promises accessible, free vaccination for their children, adding a critical layer of protection during the vulnerable early years. This means fewer illnesses, decreased antibiotic use, and improved quality of life for children and communities. Healthcare providers can confidently recommend TCV as part of the routine immunization schedule, reinforcing preventive health practices.​

Conclusion

Inclusion of the Typhoid Conjugate Vaccine in India’s Universal Immunisation Programme is a scientifically grounded, cost-effective, and equitable public health strategy. It addresses a significant disease burden, supports antimicrobial resistance control, and enhances child health outcomes. Efforts should focus now on nationwide implementation, addressing the remaining knowledge gaps through targeted research, and ensuring robust monitoring to maximize public health benefits.

Medical Disclaimer:

This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.

References